Findings from the phase 3 SIERRA study showed that Iomab-B was associated with a higher durable complete response rate vs ...

At only seven years old, Tabib was diagnosed with acute myeloid leukemia, a diagnosis that forever changed her life.

PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced ...

With FDA approval for imetelstat and solid financials, Geron shows great promise in MDS treatment. Read more on GERN stock ...

Annamycin is currently being evaluated in continuing clinical trials for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. Annamycin has fast ...

TC Biopharm (NASDAQ: TCBP) , a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, has announced a key step in its ...

I was diagnosed with Chronic Myeloid Leukemia, a blood cancer that now in 2024 has excellent survival rates if your body can ...

Sutro Biopharma specializes in ADCs for oncology and shows promise with STRO-002 for ovarian cancer and collaborations with ...

ONCO Prime is a cutting-edge drug discovery platform identifying novel synthetic lethal targets using patient-derived primary cell cultures. Initial data have identified potentially novel drug targets ...

US FDA approves anti-CD38 therapy, Sarclisa in combo with standard-of-care treatment for adult patients with NDMM who are not eligible for transplant: Paris Tuesday, September 24, ...

Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free ...